SVCM
XFOR icon

Saturn V Capital Management’s X4 Pharmaceuticals XFOR Stock Holding History

Saturn V Capital Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.6M Buy
6,973,343
+516,697
+8% +$2.12M 4.67% 11
2026
Q1 		$26.7M Buy
6,456,646
+656,116
+11% +$2.46M 4.83% 10
2025
Q4 		$23.2M Buy
+5,800,530
New +$21.1M 4.26% 11

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Saturn V Capital Management's XFOR Position: Q2 2026 in Review

Saturn V Capital Management increased its X4 Pharmaceuticals (XFOR) stake by 8% in Q2 2026, buying an estimated $2.12M and bringing the position to 6,973,343 shares worth $32.6M. The position accounts for 4.67% of the portfolio, ranked #11.

Saturn V Capital Management first reported a position in XFOR in Q4 2025 and has held it in 3 quarters since. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

  • Saturn V Capital Management held 6,973,343 shares of X4 Pharmaceuticals worth $32.6M as of Q2 2026.
  • Saturn V Capital Management bought 516,697 X4 Pharmaceuticals shares in Q2 2026, an estimated $2.12M.
  • X4 Pharmaceuticals made up 4.67% of Saturn V Capital Management's portfolio in Q2 2026, its #11 holding.
  • Saturn V Capital Management first reported a position in X4 Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Saturn V Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.